Reproduction in vitro of a quasispecies from a hepatitis C virus-infected patient and determination of factors that influence selection of a dominant species

Journal of Virology

Volumn 85, Issue 7, 2011, Pages 3408-3414

  Kawaguchi, Kazunori ^a,b   Faulk, Kristina ^a   Purcell, Robert H ^a   Emerson, Suzanne U ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN E2;

ARTICLE; CONTROLLED STUDY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IN VITRO STUDY; NONHUMAN; PLASMID; PRIORITY JOURNAL; VIROGENESIS; VIRUS INFECTIVITY; VIRUS MUTATION; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

ANTIBODIES, NEUTRALIZING; CELL CULTURE TECHNIQUES; CELL LINE; CLONING, MOLECULAR; CROSS REACTIONS; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HEPATOCYTES; HUMANS; MUTATION; RECOMBINATION, GENETIC; SERIAL PASSAGE; TRANSFECTION; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

HEPACIVIRUS; HEPATITIS C VIRUS;

EID: 79952609217     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02554-10     Document Type: Article

References (21)

1. Bankwitz, D., et al. 2010. Hepatitis C virus hypervariable region 1 modulates receptor interactions, conceals the CD81 binding site, and protects conserved neutralizing epitopes. J. Virol. 84:5751-5763.
2. Bartosch, B., J. Dubuisson, and F. L. Cosset. 2003. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197:633-642.
3. Bukh, J., R. H. Miller, and R. H. Purcell. 1995. Genetic heterogeneity of hepatitis C virus: quasispecies and genotypes. Semin. Liver Dis. 15:41-63.
4. Farci, P., et al. 1996. Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc. Natl. Acad. Sci. U. S. A. 93:15394-15399.
5. Forns, X., et al. 2000. Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc. Natl. Acad. Sci. U. S. A. 97:13318-13323.
6. Ge, D., et al. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461:399-401.
7. Gottwein, J. M., et al. 2009. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 49:364-377.
8. Lindenbach, B. D., and C. M. Rice. 2007. Flaviviridae: the viruses and their replication, p. 1101-1152. In D. M. Knipe et al. (ed.), Fields virology, 5th ed., vol. 1. Lippincott Williams & Wilkins, Philadelphia, PA.
9. Mbow, M. L., and R. T. Sarisky. 2004. What is disrupting IFN-alpha's antiviral activity? Trends Biotechnol. 22:395-399.
10. Prentoe, J., et al. 1 December 2010. Hypervariable region 1 differentially impacts viability of hepatitis C genotype 1-6 strains and impairs virus neutralization. J. Virol. doi:10.1128/JVI.01594-10.
11. Ray Kim, W. 2002. Global epidemiology and burden of hepatitis C. Microbes Infect. 4:1219-1225.
12. Russell, R. S., et al. 2008. Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc. Natl. Acad. Sci. U. S. A. 105:4370-4375.
13. Scarselli, E., et al. 2002. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21:5017-5025.
14. Shimakami, T., R. E. Lanford, and S. M. Lemon. 2009. Hepatitis C: recent successes and continuing challenges in the development of improved treatment modalities. Curr. Opin. Pharmacol. 9:537-544.
15. Shimizu, Y. K., et al. 1996. A hyperimmune serum against a synthetic peptide corresponding to the hypervariable region 1 of hepatitis C virus can prevent viral infection in cell cultures. Virology 223:409-412. (Pubitemid 26319606)
16. Stoll-Keller, F., H. Barth, S. Fafi-Kremer, M. B. Zeisel, and T. F. Baumert. 2009. Development of hepatitis C virus vaccines: challenges and progress. Exp. Rev. Vaccines 8:333-345.
17. Tellier, R., J. Bukh, S. U. Emerson, R. H. Miller, and R. H. Purcell. 1996. Long PCR and its application to hepatitis viruses: amplification of hepatitis A, hepatitis B, and hepatitis C virus genomes. J. Clin. Microbiol. 34:3085-3091.
18. Thompson, A., K. Patel, H. Tillman, and J. G. McHutchison. 2009. Directly acting antivirals for the treatment of patients with hepatitis C infection: a clinical development update addressing key future challenges. J. Hepatol. 50:184-194.
19. Vieyres, G., J. Dubuisson, and A. H. Patel. 17 November 2010. Characterization of antibody-mediated neutralization directed against the hypervariable region 1 of hepatitis C virus E2 glycoprotein. J. Gen. Virol. doi:10.1099/vir.0.028092-0.
20. Wakita, T., et al. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
21. Yi, M., Y. Ma, J. Yates, and S. M. Lemon. 2007. Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J. Virol. 81:629-638.